Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
B
Baku Acharya
Researcher
Also affiliated: Sri Venkateswara University (1985); B.P. Koirala Memorial Cancer Hospital (2010); Kathmandu University (2019–2020); Mississippi State University (2020)
Faculty Researcher
8 h-index
86 pubs
204 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Baku Acharya's research focuses on the development and application of small-molecule inhibitors for targeted cancer therapies. His work investigates the targeting of specific kinases, such as rearranged during transfection (RET) and FLT3, which are implicated in various cancers including lung neoplasms, lymphomas, and acute myeloid leukemia. Acharya has published on the perspectives of small-molecule inhibitor development, including strategies for limiting conformational flexibility and the patent landscape of RET kinase inhibitors. His recent publications explore novel therapeutic targets, such as NEK2 in lymphoma, and the discovery of bifunctional inhibitors and compounds with improved solubility for DNA-PKcs. He also studies the targeting of G-quadruplex structures in oncogene promoters. Acharya collaborates extensively with researchers at the University of Arkansas for Medical Sciences, including Ying-Zhi Xu, Mason McCrury, Kennith Swafford, and Brendan Frett, with whom he shares a significant number of co-authored publications.
Metrics
- h-index: 8
- Publications: 86
- Citations: 204
Selected Publications
-
Epigenetic dysregulation and therapeutic targeting of <scp>RET</scp> receptor tyrosine kinase in high‐risk <scp> <i>KMT2A</i> </scp> ‐rearranged acute myeloid leukaemia (2025)
-
Discovery of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRK/PTK6 inhibitors (2025)
-
Discovery of Novel 1h-Pyrazolo[3,4-D]Pyrimidine Derivatives as Brk/Ptk6 Inhibitors (2025)
-
Transforming growth factor β receptor 1 and mitogen-activated protein 4 kinase 4 dual inhibitor, TK-850, reduces renal fibrosis in unilateral ureteral–obstructed mice (2025)
-
Epigenetic Dysregulation and Therapeutic Targeting of RET Receptor Tyrosine Kinase in High-Risk KMT2A-Rearranged Pediatric Acute Myeloid Leukemia (2025)
-
Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441 (2024)
-
Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGFβR1/MAP4K4 (2024)
-
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors (2024)
-
557 Dual TGFβR1/MAP4K4 inhibitor reduces kidney injury in a mouse model of renal fibrosis. (2024)
Collaboration Network
Top Collaborators
Brendan Frett
University of Arkansas for Medical Sciences
9 shared publications
In database
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
Showing 5 of 9 shared publications
Debasmita Saha
Discovery Institute (US)
6 shared publications
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
Showing 5 of 6 shared publications
Daniel W. Armstrong
University of Arkansas for Medical Sciences
4 shared publications
In database
- FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
Naga Rajiv Lakkaniga
Indian Institute of Technology Dhanbad (IN)
3 shared publications
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
Maha Hanafi
Cairo University
3 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
Katie R. Ryan
University of Arkansas for Medical Sciences
2 shared publications
In database
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
Noemi Garcia Garcia
University of Arkansas for Medical Sciences
2 shared publications
In database
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
Kennith Swafford
University of Arkansas for Medical Sciences
2 shared publications
In database
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
Ying-Zhi Xu
University of Arkansas for Medical Sciences
2 shared publications
In database
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
Mason McCrury
University of Arkansas for Medical Sciences
2 shared publications
In database
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
Samantha Kendrick
University of Arkansas for Medical Sciences
2 shared publications
In database
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
Baha’a Jabali
University of Arkansas for Medical Sciences
2 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
Erica Lane Smith
University of Arkansas for Medical Sciences
1 shared publication
In database
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
Sayem Miah
University of Arkansas for Medical Sciences
1 shared publication
In database
- Targeting TGF-β: Triumphs and Challenges
Thomas Raney
University of Arkansas for Medical Sciences
1 shared publication
In database
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
Similar Researchers
Based on overlapping research topics
Brendan Frett
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Disease Mechanisms Research
Sydnye L. Shuttleworth
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Lymphoma Diagnosis and Treatment
Disease Mechanisms Research
Cade Richesin
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Lymphoma Diagnosis and Treatment
Disease Mechanisms Research
Jim Angeles
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Lymphoma Diagnosis and Treatment
Disease Mechanisms Research
Robin Eluvathingal
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Cancer-related molecular mechanisms research
Gunaganti Naresh
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Disease Mechanisms Research